I have published several scientific papers:
GOSALBES, MJ., PÉREZ.-ARELLANO, I., ESTEBAN, CD., GALÁN, JL. PÉREZ-MARTÍNEZ, G.
Use of lac regulatory elements for gene expression in Lactobacillus casei.
2001, Le Lait 81:29-35.
PÉREZ-ARELLANO, I, ZUÑIGA, M., PEREZ-MARTINEZ, G. Construction of wide-host range vectors for the cloning of DNA fragments protected by transcriptional terminators.
2001, Plasmid 46, 106-116.
GIL M.TERESA,* PEREZ-ARELLANO, I *, BUESA J, PÉREZ-MARTÍNEZ, G.
* These authors have contributed equally.
Secretion of the vp8* protein in Lactococcus lactis.
2001, FEMS Microbiol Letters. 203, 269-274.
PEREZ-ARELLANO, I, PÉREZ-MARTÍNEZ, G.
Structural features of the lac promoter affecting gusA expression in Lactobacillus casei.
2002, Current Microbiology 45(3), 191-6.
2003, FEMS Microbiol Letters 222 (1), 123-7.
PEREZ-ARELLANO I, GIL-ORTIZ F, CERVERA J, RUBIO V.
Glutamate-5-kinase from Escherichia coli: gene cloning, overexpression, purification and crystallization of the recombinant enzyme and preliminary X-ray studies.
2004, Acta Crystallogr D Biol Crystallogr. 60, 2091-4.
PEREZ-ARELLANO I, RUBIO V, CERVERA J.
Dissection of Escherichia coli glutamate 5-kinase: functional impact of the deletion of the PUA domain.
2005, FEBS Lett. 579(30):6903-8.
AIRES KA, CIANCIARULLO AM, CARNEIRO SM, VILLA LL, BOCCARDO E, PEREZ-MARTINEZ G, PEREZ-ARELLANO I, OLIVEIRA ML, HO PL.
Production of HPV-16 L1 Virus-Like Particles by recombinant Lactobacillus casei.
2006, Appl Environ Microbiol. 72(1):745-52.
PEREZ-ARELLANO I, RUBIO V, CERVERA J.
Mapping active site residues in glutamate-5-kinase. The substrate glutamate and the feed-back inhibitor proline bind at overlapping sites.
2006, FEBS Letters, 580, 6247-6253.
MARCO-MARÍN C, GIL-ORTIZ F, PEREZ-ARELLANO I, CERVERA J, FITA I AND RUBIO V.
A novel two domain architecture within the amino acid kinase family revealed by the crystal structure of Escherichia coli glutamate 5-kinase.
2007, J. Mol. Biol. 367, 1431–1446
PEREZ-ARELLANO I, GALLEGO J, CERVERA J.
The PUA domain - a structural and functional overview.
2007 FEBS J. 274, 4972-84.
PÉREZ-ARELLANO I, GOZALBO-ROVIRA R, MARTÍNEZ AI, CERVERA J.
Expression and purification of recombinant human MCT-1 oncogene in insect cells.
Protein J. 2010 Feb;29(2):69-74.
PÉREZ-ARELLANO I, CARMONA-ALVAREZ F, MARTÍNEZ AI, RODRÍGUEZ-DÍAZ J, CERVERA J.
Pyrroline-5-carboxylate synthase and proline biosynthesis: from osmotolerance to rare metabolic disease.
Protein Sci. 2010 Mar;19(3):372-82. Review.
PÉREZ-ARELLANO I, CERVERA J.
Glutamate kinase from Thermotoga maritima: characterization of a thermophilic enzyme for proline biosynthesis.
Extremophiles. 2010 Jul;14(4):409-15.
MARTÍNEZ AI, PÉREZ-ARELLANO I, PEKKALA S, BARCELONA B, CERVERA J.
Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency.
Mol Genet Metab. 2010 Dec;101(4):311-23.
PÉREZ-ARELLANO I, CARMONA-ALVAREZ F, GALLEGO J, CERVERA, J.
Molecular mechanisms modulating glutamate kinase activity. Identification of the proline feedback inhibitor binding site. J Mol Biol. 2010, 404(5):890-901.
DÍEZ C, MARTÍNEZ AI, PEKKALA S, BARCELONA B, PÉREZ-ARELLANO I, SUMMAR M, RUBIO V, CERVERA J.
Molecular characterization of carbamoyl phosphate synthetase (CPSI) deficiency using human recombinant CPSI as a key tool.
Human Mutation, 2013 May 3. doi: 10.1002/humu.22349.
PÉREZ-ARELLANO I, SPINOLA-NAMIBIA M, BRAVO J.
Human Drg1 is a potassium dependent Gtpase activated by Lerepo4.
FEBS J. 2013 May 25. doi: 10.1111/febs.12356.
I have published a chapter of a scientific book:
MONEDERO V, PÉREZ-ARELLANO I, VIANA R, ZÚÑIGA M, BUESA J, MONTAVA R, RODRÍGUEZ-DÍAZ J, LEE HO P, SARNO DE OLIVEIRA L, Y PÉREZ-MARTÍNEZ G.
Diseño de probióticos como vectores de vacunas orales y otras moléculas terapéuticas. En: Microorganismos y salud. Bacterias lácticas y bifidobacterias probióticas. Book chapter 14, pág. 172-183. (Juan Miguel Rodríguez Gómez, Ed), Editorial Complutense, Madrid. (2007)
I am part of a patent:
GOSALBES SOLER MJ, PÉREZ ARELLANO I, ESTEBAN NIETO CD, GALÁN JL Y PÉREZ MARTÍNEZ G.
TITULO:
Uso de la secuencia de nucleótidos del promotor de la lactosa de lactobacillus casei para regular la expresión génica a través de una proteína antiterminadora.
Nº registro 2000-00897
PRIORITY COUNTRY SPAIN PRIORITY DATE 7 de Abril de 2000
ENTITY CSIC
OTHER COUNTRIES Europe
I have solved the 3D structure of a mutant enzyme of glutamate kinase without the PUA domain of Escherichia coli. PDB id: 2W21
-REDACTORA MÉDICA DEL ARTÍCULO:
As a medical writer I wrote the following paper: Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, Del Alba AG, Castellano D, Gallardo E, Anido U, Del Muro XG, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J. LANCET ONCOLOGY, 2017 May;18(5):672-681.